Clinical guidance demonstrates risks of ovarian recovery with aromatase inhibitors after chemotherapy-induced amenorrhea, indicating a need for sensitive monitoring.
AIs may promote recovery of ovarian function in some women with chemotherapy-induced amenorrhea and should be used with caution. Biochemical monitoring of ovarian function requires highly sensitive immunoassays. Guidelines for the selection and delivery of adjuvant endocrine therapy in such patients are proposed.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: